Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

MRI in Women With Newly Diagnosed Breast Cancer Prior to Breast Conserving Surgery

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2008 by Stanford University.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00695916
First received: June 10, 2008
Last updated: December 12, 2008
Last verified: December 2008
  Purpose

To see if performing breast MRI before a lumpectomy will help the surgeon successfully remove the entire cancer with normal tissue margins in a single operation thereby reducing the need for additional surgical procedures. The study will also measure how well MRI can find unsuspected cancers in the same breast as the known cancer; how well MRI will find unsuspected cancers in the opposite breast; how often MRI will generate false positive MRI findings; whether routinely incorporating breast MRI delays care or adds unnecessary cost; and, whether breast MRI is able to reduce the frequency of cancer recurrence in the treated breast or elsewhere in the body.


Condition Intervention Phase
Breast Cancer
Procedure: Breast MRI
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Randomized Trial of Breast MRI in Women With Newly Diagnosed Breast Cancer Prior to Breast Conserving Surgery

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • To determine whether pre-lumpectomy breast MRI reduces the frequency of repeat lumpectomy in women with DCIS < 5 cm or T1 or T2 invasive breast cancer

Secondary Outcome Measures:
  • To determine how often MRI will detect occult multifocal or multicentric disease
  • To determine how often MRI will miss occult DCIS or invasive cancer subsequently detected on surgical pathology
  • To determine the frequency with which breast MRI changes the surgical plan
  • To determine the frequency of false positive MRI findings requiring biopsy
  • To measure whether MRI reduces the frequency of repeat lumpectomy to a greater extent in women with mammographically dense vs fatty breasts
  • To measure whether preoperative MRI is associated with enhanced postoperative cosmesis
  • To measure whether preoperative MRI alters cost of care
  • To measure the degree and extent to which preoperative MRI lengthens the time required to deliver care
  • To measure whether preoperative MRI increases the rate of patient directed ("unnecessary") mastectomy
  • To measure whether MRI decreases the risk of ipsilateral breast tumor recurrence
  • To measure disease-free survival without/with preoperative breast MRI
  • To measure overall survival without/with preoperative MRI

Estimated Enrollment: 180
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • DCIS less than 5 cm. T1/T2 invasive breast cancer. Patient is a suitable candidate for breast conservation and wishes this as the primary clinical approach
  • No breast MRI within the past year. Prior core biopsy, but no prior excision allowed. Patient has completed conventional imaging workup with mammography ultrasound as indicated and there is no clinical indication for breast MRI.
  • Women with age >= 18. No ethnic restrictions.
  • No life expectancy restrictions.
  • Performance status not a factor.
  • No requirements for organ or marrow function.
  • Ability to understand and the willingness to sign a written informed consent document.&#xA;

Exclusion Criteria:

  • Patient is unable to complete a breast MRI due to such factors as hardware and claustrophobia.
  • No limitations as to other investigational agents. Patients who have received neoadjuvant chemotherapy will not be included in the study due to the limitations of MRI interpretation after neoadjuvant chemotherapy and because this represents a distinct scenario for interpretation of breast MRI in comparison with untreated patients.
  • There are no comorbidities that would preclude entry into the study unless the patient is unable to lay still for breast MRI scanning.
  • There are fewer reactions to MRI contrast media, but if there is such a history, the patient will be excluded from consideration.
  • There are no exclusion criteria based on concomitant medications.
  • There are no other agent specific exclusion criteria.
  • Pregnancy is considered a contraindication given the uncertain effects of breast MRI on the fetus.
  • Cancer survivors are candidates for the study unless the patient has a prior ipsilateral breast tumor.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00695916

Contacts
Contact: Sally Bobo (650) 736-1472 sbobo@stanford.edu

Locations
United States, California
Stanford University School of Medicine Not yet recruiting
Stanford, California, United States, 94305
Contact: Sally Bobo    650-736-1472    sbobo@stanford.edu   
Contact: Cancer Clinical Trials Office    (650) 498-7061      
Principal Investigator: Frederick M. Dirbas         
Sub-Investigator: Debra M Ikeda         
Sub-Investigator: Bruce Lewis Daniel         
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Frederick M. Dirbas Stanford University
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00695916     History of Changes
Other Study ID Numbers: SU-12102007-930, 98272, BRSNSTU0025
Study First Received: June 10, 2008
Last Updated: December 12, 2008
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms
Neoplasms by Site
Skin Diseases

ClinicalTrials.gov processed this record on November 20, 2014